在晚期帕金森病中,震对利沃多巴的反应很强
Bart E K S Swinnen1, Henrieke L Frequin1, Yarit Wiggerts2
1Department of Neurology and Clinical Neurophysiology, Amsterdam University Medical Centers, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands.
Movement disorders clinical practice
|November 9, 2024
概括
在晚期帕金森病 (PD) 中,震显示出比布拉迪基尼西亚和刚性更大的勒沃多巴反应. 不响应levodopa的震是罕见的,挑战了关于PD症状管理的先前假设.
科学领域:
- 神经学 神经学
- 运动障碍 运动障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 的震通常被认为与其他运动症状相比,对利沃多巴的反应较差.
- 在PD中,勒沃多巴耐药的概念被广泛接受,影响了治疗策略.
研究的目的:
- 评估莱沃多巴在治疗晚期帕金森病中震,勃拉迪基尼西亚和刚性的有效性.
- 为了确定前期PD患者队列中对levodopa不反应的震的患病率.
主要方法:
- 对526名帕金森病患者进行深度脑刺激查的回顾性分析.
- 在服用勒沃多巴后,评估运动症状的改善.
主要成果:
- 与布拉迪基尼西亚和刚性相比,的比例改善 (86.8%) 和完全解脱 (67.9%) 显著更高.
- 没有对levodopa反应的震 (<25%的改善) 是不常见的 (4.0%),与较高的布拉迪基尼西亚 (19.4%) 和刚性 (9.8%) 相比.
- 在三个核心运动症状中,勒沃多巴反应的效应大小是可比的.
结论:
- 与普遍认为的相反,晚期帕金森病的震对利沃多巴的反应很强.
- 莱沃多巴不响应的震在晚期PD中并不常见,这表明莱沃多巴仍然是主要的治疗选择.
- 这些发现需要对帕金森病运动症状的治疗模式进行重新评估.
相关概念视频
Parkinson's Disease: Treatment
222
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
222
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K


